Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-05-24
2011-05-24
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S233000, C546S234000
Reexamination Certificate
active
07947714
ABSTRACT:
The present invention is directed to piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.
REFERENCES:
patent: 5922717 (1999-07-01), Pieper et al.
patent: 2007/0105902 (2007-05-01), Lindsley et al.
patent: 2007/0249606 (2007-10-01), Lindsley et al.
patent: 2007/0254880 (2007-11-01), Blackaby et al.
patent: WO 03/088908 (2003-10-01), None
patent: WO 2005/046601 (2005-05-01), None
patent: WO 2006/039221 (2006-04-01), None
patent: WO 2006/067529 (2006-06-01), None
Hallett David
Lindsley Craig W.
Naylor Elizabeth M.
Nolt M. Brad
Theberge Cory R.
Anderson Rebecca
Hess Susan L.
Merck Sharp & Dohme Corp.
Thies John Eric
Yuro Raynard
LandOfFree
Piperidine glycine transporter inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperidine glycine transporter inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperidine glycine transporter inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2666807